Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hernexeos (zongertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Sino Biopharm

Drug class:

HER2 exon 20 mutation inhibitor

Related drugs:

‹

sevabertinib (1)

sevabertinib (1)

›

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 overexpression	Solid Tumor	HER-2 overexpression	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2	zongertinib Sensitive: C2 – Inclusion Criteria zongertinib Sensitive : C2
HER-2 positive	Cholangiocarcinoma	HER-2 positive	Cholangiocarcinoma	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 positive	Esophageal Cancer	HER-2 positive	Esophageal Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 rearrangement	Solid Tumor	HER-2 rearrangement	Solid Tumor	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3	zongertinib Sensitive: C3 – Early Trials zongertinib Sensitive : C3
HER-2 mutation	Esophageal Cancer	HER-2 mutation	Esophageal Cancer	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4
HER-2 mutation	Cholangiocarcinoma	HER-2 mutation	Cholangiocarcinoma	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4	zongertinib Sensitive: C4 – Case Studies zongertinib Sensitive : C4